Who
Jack W. Callicutt
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Galectin Therapeutics; Chief Financial Officer, Vystar; VP-Finance&Admin, Chf Acct Off, Corautus Genetics.
In numbers
- Trades disclosed
- 121
- Buys
- 4
- Sells
- 18
- Bought
- $22K
- Sold
- $4.2M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 15 May 2006
- Last trade
- 16 Jan 2026
- Last filed
- 21 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 6 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K20,354 at $3.67 | filing |
| 6 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $75K20,354 at $3.67 | filing |
| 5 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $100K25,732 at $3.90 | filing |
| 5 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $100K25,732 at $3.90 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | —60,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $58K13,914 at $4.20 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | —60,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $58K13,914 at $4.20 | filing |
| 1 Jan 2026filed 6 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,000 at $0.00 | filing |
| 1 Jan 2026filed 6 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,000 at $0.00 | filing |
| 18 Nov 2025filed 19 Nov 2025 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,120 at $0.00 | filing |
| 18 Nov 2025filed 19 Nov 2025 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,190 at $0.00 | filing |
| 18 Nov 2025filed 19 Nov 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $56K28,100 at $1.98 | filing |
| 18 Nov 2025filed 19 Nov 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $175K28,100 at $6.22 | filing |
| 18 Nov 2025filed 19 Nov 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $20K18,210 at $1.11 | filing |
| 18 Nov 2025filed 19 Nov 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $113K18,210 at $6.22 | filing |
News
No headline names them, or the companies they trade most, lately.